BARRX Medical, Inc. today announced the initiation of a landmark human study titled "Ablation of Intestinal Metaplasia Containing Dysplasia: a Multi-Center, Randomized, Sham-Controlled Trial." The AIM Dysplasia Trial will compare the effectiveness of the HALO360 System against the current standard of care for Barrett's esophagus, which includes regular endoscopic biopsy surveillance and appropriate medical management of associated acid reflux disease (also called GERD). Barrett's esophagus, often caused by chronic GERD, is a pre-cancerous change to the lining of the esophagus that affects approximately three million U.S. adults. Barrett's sufferers are at increased risk for developing a dangerous type of cancer called esophageal adenocarcinoma, currently the fastest growing cancer in the U.S. The study is the first to compare radio frequency (RF) ablation therapy against the current standard of care for the treatment of Barrett's esophagus.
